Brief: BioVaxys Enters Agreement With Wuxi Biologics To Synthesize Proteins For Its SARS-CoV-2 Vaccine
15/03/2021 12:29
March 15 (Reuters) - Biovaxys Technology Corp BIOV.CD :
* BIOVAXYS ENTERS MAJOR BIOPRODUCTION AGREEMENT WITH WUXI
BIOLOGICS (HONG KONG) LTD. TO SYNTHESIZE PROTEINS FOR ITS
SARS-COV-2 VACCINE AND COVID-T™ IMMUNODIAGNOSTIC PROGRAMS
Source text for Eikon: ID:nCNWThWjKa
Further company coverage: BIOV.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biovaxys Technology
See all newsBrief: Biovaxys Appoints Former Sanofi Vaccines Executive To Board Of Directors
Brief: Biovaxys Announces Life Offering
Brief: Biovaxys And Horizon Technology Finance Execute Amendment To Asset Purchase Agreement
Brief: Biovaxys And Horizon Technology Finance Execute Amendment To Asset Purchase Agreement
Brief: Biovaxys Announces Consolidation And Concurrent Brokered Private Placement Offering For Gross Proceeds Of Up To $3,000,000